Lanean...
Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria
BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal, hematopoietic stem cell disorder that manifests with hemolytic anemia and bone marrow failure. Eculizumab has been shown to improve anemia, decrease intravascular hemolysis, and reduce the risk of thrombosis. DESIGN AND METHODS: This...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2012
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3673783/ https://ncbi.nlm.nih.gov/pubmed/23046169 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.12021 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|